GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Phase 2
Not yet recruiting
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: RO7837195Drug: RO7837195 Matched Placebo
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06979336
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 546
- Registration Number
- NCT06850922
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸Associated Retinal Consultants PC, Phoenix, Arizona, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: RO7497372
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT06847854
- Locations
- 🇺🇸
Retinal Consultants of AZ, Ltd, Peoria, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retinal Consultants Medical Group, Modesto, California, United States
A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06835465
- Locations
- 🇺🇸
Fortrea Dallas CRU, Dallas, Texas, United States
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06734208
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06693908
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06690138
- Locations
- 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States
A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT06677957
- Locations
- 🇺🇸
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Phase 1
Active, not recruiting
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06674993
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: Phase I Arm ADrug: Phase I Arm B
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 410
- Registration Number
- NCT06619587
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇦🇺St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Peter Maccallum Cancer Centre, Parkville, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath